Additionally, as above-mentioned, HR-deficient cells with a reduced level of Polθ expression are more sensitive to radiation and probably other antitumor agents such as chemotherapy, cisplatin, and mitomycin C. Furthermore, it is possible that several DNA lesions are repaired only via a Polθ mediated mechanism, hence we can hypothesize that cancer cells with such lesions may be even more sensitive during treatment with Polθi [74]. Here, POLI is linked to cancer.